S&P Futures
4,263.75 -17.25 (-0.40%) Dow Futures
33,614.00 -104.00 (-0.31%) Nasdaq Futures
13,513.25 -64.50 (-0.48%) Russell 2000 Futures
2,007.30 -9.60 (-0.48%) Crude Oil
91.09 -1.00 (-1.09%) Gold
1,804.30 -11.20 (-0.62%)
Arvinas, Inc. (ARVN)
After hours:
- Zacks
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “This is an exciting time at Arvinas as we remain on track to initiate two pivotal programs with ARV-471 in metastatic breast cancer in the second half of this year, have a clear development pathway fo
- GlobeNewswire
Arvinas Appoints John Northcott as Chief Commercial Officer
NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO). “John is an excellent addition to the Arvinas leadership team, and I am confident that his experience and impressive product development and commercialization track record will play an imp
